222 related articles for article (PubMed ID: 12068014)
1. MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation.
Jin Y; Zeng SX; Dai MS; Yang XJ; Lu H
J Biol Chem; 2002 Aug; 277(34):30838-43. PubMed ID: 12068014
[TBL] [Abstract][Full Text] [Related]
2. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins.
Kobet E; Zeng X; Zhu Y; Keller D; Lu H
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12547-52. PubMed ID: 11070080
[TBL] [Abstract][Full Text] [Related]
3. The histone acetyltransferase PCAF regulates p21 transcription through stress-induced acetylation of histone H3.
Love IM; Sekaric P; Shi D; Grossman SR; Androphy EJ
Cell Cycle; 2012 Jul; 11(13):2458-66. PubMed ID: 22713239
[TBL] [Abstract][Full Text] [Related]
4. MDM2 mediates p300/CREB-binding protein-associated factor ubiquitination and degradation.
Jin Y; Zeng SX; Lee H; Lu H
J Biol Chem; 2004 May; 279(19):20035-43. PubMed ID: 14769800
[TBL] [Abstract][Full Text] [Related]
5. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage.
Di Stefano V; Soddu S; Sacchi A; D'Orazi G
Oncogene; 2005 Aug; 24(35):5431-42. PubMed ID: 15897882
[TBL] [Abstract][Full Text] [Related]
6. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation.
Ito A; Kawaguchi Y; Lai CH; Kovacs JJ; Higashimoto Y; Appella E; Yao TP
EMBO J; 2002 Nov; 21(22):6236-45. PubMed ID: 12426395
[TBL] [Abstract][Full Text] [Related]
7. p73gamma transactivates the p21 promoter through preferential interaction with the p300/CBP-associated factor in human prostate cancer cells.
Momii Y; Izumi H; Shiota M; Onitsuka T; Abe T; Kobayashi H; Miyamoto N; Uchiumi T; Kohno K
Oncol Rep; 2007 Aug; 18(2):411-6. PubMed ID: 17611664
[TBL] [Abstract][Full Text] [Related]
8. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases.
Barlev NA; Liu L; Chehab NH; Mansfield K; Harris KG; Halazonetis TD; Berger SL
Mol Cell; 2001 Dec; 8(6):1243-54. PubMed ID: 11779500
[TBL] [Abstract][Full Text] [Related]
9. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1).
Zhao Y; Lu S; Wu L; Chai G; Wang H; Chen Y; Sun J; Yu Y; Zhou W; Zheng Q; Wu M; Otterson GA; Zhu WG
Mol Cell Biol; 2006 Apr; 26(7):2782-90. PubMed ID: 16537920
[TBL] [Abstract][Full Text] [Related]
10. Defective p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with mdm2 gene amplification.
Knights CD; Liu Y; Appella E; Kulesz-Martin M
J Biol Chem; 2003 Dec; 278(52):52890-900. PubMed ID: 14555661
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region.
Somasundaram K; El-Deiry WS
Oncogene; 1997 Mar; 14(9):1047-57. PubMed ID: 9070653
[TBL] [Abstract][Full Text] [Related]
12. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2.
Linares LK; Kiernan R; Triboulet R; Chable-Bessia C; Latreille D; Cuvier O; Lacroix M; Le Cam L; Coux O; Benkirane M
Nat Cell Biol; 2007 Mar; 9(3):331-8. PubMed ID: 17293853
[TBL] [Abstract][Full Text] [Related]
13. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage.
Liu L; Scolnick DM; Trievel RC; Zhang HB; Marmorstein R; Halazonetis TD; Berger SL
Mol Cell Biol; 1999 Feb; 19(2):1202-9. PubMed ID: 9891054
[TBL] [Abstract][Full Text] [Related]
14. The histone acetyltransferase activity of PCAF cooperates with the brahma/SWI2-related protein BRG-1 in the activation of the enhancer A of the MHC class I promoter.
Brockmann D; Lehmkühler O; Schmücker U; Esche H
Gene; 2001 Oct; 277(1-2):111-20. PubMed ID: 11602348
[TBL] [Abstract][Full Text] [Related]
15. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2.
Ito A; Lai CH; Zhao X; Saito S; Hamilton MH; Appella E; Yao TP
EMBO J; 2001 Mar; 20(6):1331-40. PubMed ID: 11250899
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of p53 degradation by Mdm2 acetylation.
Wang X; Taplick J; Geva N; Oren M
FEBS Lett; 2004 Mar; 561(1-3):195-201. PubMed ID: 15013777
[TBL] [Abstract][Full Text] [Related]
17. The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells.
Watts GS; Oshiro MM; Junk DJ; Wozniak RJ; Watterson S; Domann FE; Futscher BW
Neoplasia; 2004; 6(3):187-94. PubMed ID: 15153330
[TBL] [Abstract][Full Text] [Related]
18. DNA damage activates p53 through a phosphorylation-acetylation cascade.
Sakaguchi K; Herrera JE; Saito S; Miki T; Bustin M; Vassilev A; Anderson CW; Appella E
Genes Dev; 1998 Sep; 12(18):2831-41. PubMed ID: 9744860
[TBL] [Abstract][Full Text] [Related]
19. Human immunodeficiency virus type-1 Tat/co-activator acetyltransferase interactions inhibit p53Lys-320 acetylation and p53-responsive transcription.
Harrod R; Nacsa J; Van Lint C; Hansen J; Karpova T; McNally J; Franchini G
J Biol Chem; 2003 Apr; 278(14):12310-8. PubMed ID: 12501250
[TBL] [Abstract][Full Text] [Related]
20. Ets1 is required for p53 transcriptional activity in UV-induced apoptosis in embryonic stem cells.
Xu D; Wilson TJ; Chan D; De Luca E; Zhou J; Hertzog PJ; Kola I
EMBO J; 2002 Aug; 21(15):4081-93. PubMed ID: 12145208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]